


## (S,R,S)-AHPC-PEG2-NH2

<b>Cat. No.:</b>	HY-103603A		
<b>CAS No.:</b>	2010159-60-9		
<b>Molecular Formula:</b>	C <sub>28</sub> H <sub>41</sub> N <sub>5</sub> O <sub>6</sub> S		
<b>Molecular Weight:</b>	575.72		
<b>Target:</b>	E3 Ligase Ligand-Linker Conjugates		
<b>Pathway:</b>	PROTAC		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### BIOLOGICAL ACTIVITY

<b>Description</b>	(S,R,S)-AHPC-PEG2-NH2 (VH032-PEG2-NH2) is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in the synthesis of PROTACs <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	VHL
<b>In Vitro</b>	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Chan KH, et al. Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds. J Me

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA